GWSG
AKBA icon

GPS Wealth Strategies Group’s Akebia Therapeutics AKBA Stock Holding History

GPS Wealth Strategies Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,625
Closed -$9.9K – 604
2025
Q3 		$9.9K Hold
3,625
– – ﹤0.01% 1093
2025
Q2 		$13.2K Hold
3,625
– – ﹤0.01% 961
2025
Q1 		$6.96K Hold
3,625
– – ﹤0.01% 1081
2024
Q4 		$6.89K Hold
3,625
– – ﹤0.01% 1028
2024
Q3 		$4.79K Hold
3,625
– – ﹤0.01% 1110
2024
Q2 		$3.7K Buy
+3,625
New +$4.48K ﹤0.01% 1121

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GPS Wealth Strategies Group's AKBA Position: Q4 2025 in Review

GPS Wealth Strategies Group sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 3,625 shares — an estimated $9.9K sold.

GPS Wealth Strategies Group first reported a position in AKBA in Q2 2024 and held it in 6 quarters. The position peaked at $13.2K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • GPS Wealth Strategies Group reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 3,625 Akebia Therapeutics shares in Q4 2025, an estimated $9.9K.
  • GPS Wealth Strategies Group first reported a position in Akebia Therapeutics in Q2 2024 and held it in 6 quarters.
  • GPS Wealth Strategies Group's Akebia Therapeutics position peaked at $13.2K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2025, filed 6 Feb 2026.